Fortis Healthcare · FORTIS
Fortis keeps adding hospital beds and holds this year's margin flat after share-scheme costs
Fortis Healthcare has committed ₹3,500 crore to about 2,000 new beds, and expects this year's margin after its new employee share-scheme cost to stay around last year's 22%; the CFO said May's guidance remains "more or less" intact but would not guide beyond this year.
4 min read Published on
Published by
Inve Content team
Fortis Healthcare spent its latest results telling shareholders two things. It is expanding: about 600 hospital beds this financial year and roughly 2,000 in the pipeline, backed by ₹3,500 crore of capital spending it has already committed. And on margin it held this year steady but would look no further. Answering a question on the hospital business, chief financial officer Vivek Goyal said that for this financial year "the EBITDA margin should be flattish". In a later answer he put it in line with last year's level of around 22%, measured after the cost of the new employee share scheme.
That figure is lower than the one shareholders were given in May, but it is not measured the same way. Then, the company guided to another 1.5 percentage points of hospital EBITDA margin this year, on top of the 22.2% earned last year, which works out to about 23.7%. EBITDA here is earnings before interest, tax, depreciation and amortisation, measured against revenue. That guide came before the share scheme existed: Goyal said the scheme was rolled out after the year's budget had been set, and that it takes about 1.5% of revenue. Take that cost off May's level and it comes to about 22.2%, by our calculation, close to the figure he gave now. Management also said in May that its 25% target for the following year remained intact. Now Goyal has declined to give any margin view beyond this year while the debate over drug prices plays out.
Take the share-scheme cost off May's margin guide and it lands near the 22% management expects now
%
- FY27 as guided in May, before share-scheme cost 23.7%
- May's guide less share-scheme cost, calculated 22.2%
- FY27 as guided now, after share-scheme cost, about 22% 22%
In his first answer, Goyal said the margin guidance "more or less" remained intact, while the difficulties flagged last quarter persisted. A follow-up settled the basis: asked directly whether that 22% was after the share-scheme cost, Goyal said yes. In that later answer he also said the longer-term target would be met if the drug-price changes have no impact.
Measured before the share-scheme cost, as the company reports its segments, the hospital margin slipped to 21.5% in the first quarter of this year, below the level of a year earlier, then rose to 23.3% last quarter, above it. Put the two quarters together and the first half comes to 22.4%, calculated from the reported segment figures, a little above last year's level but short of the level May's guidance pointed to, so the second half has to run higher to reach it.
Year on year the hospital margin fell in the first quarter and rose in the second, leaving the half flat
%
First quarter
- 22.1% FY26
- 21.5% FY27
Second quarter
- 22.9% FY26
- 23.3% FY27
The headline figure flatters the picture a little. The company reported a consolidated EBITDA margin of 24.2% for last quarter, slightly above the year before, but that is before the share-scheme expense, which began this year and which Goyal said takes about 1.5% of revenue. Deduct it and the group margin was about 1.2 points lower than a year ago, by our calculation from those figures. That matters because the 25% group goal management repeated in August is meant to be reached after that cost.
Counted after the share-scheme cost, the group's margin fell from a year earlier
points
- Change before share-scheme cost 0.3 points
- Change after share-scheme cost, estimated -1.2 points
Management pointed to two pressures. Two newer hospitals, Manesar and Peepaltree, are still filling up and weighing on profit. A government circular capping prices of cancer drugs takes effect in November, and Goyal said it would hurt profitability, noting that drugs make up about a third of oncology revenue and that not all of them are covered; he did not put a figure on the effect. In May, discussing an earlier cap on drug prices for government-scheme patients, he had described the hit as one to revenue rather than margin.
The boost it is waiting for is the new block at Fortis Memorial Research Institute in Gurugram, the group's flagship, which management said in August would make the major contribution to this year's additions. Goyal said its opening should lift profitability. A year ago the company expected to commission it by the end of March; in August it said occupancy approval might come that month. Chief executive Ashutosh Raghuvanshi now says the block is ready and approvals should arrive within November.
None of this is a funding problem. The ratio of net debt to EBITDA was 0.87 at the end of September, lower than a year earlier. What has changed is how far ahead management will look. Beds are still being added, if later than planned at the flagship, and this year's margin guide holds once the share-scheme cost is counted; beyond this year, management will not guide on margins until the drug-price rules settle.
Fortis Healthcare stock page →
The record: full financial tables
Financials
Income statement, last 8 quarters
| Quarter end | Sales | YoY | Operating profit | Op. margin | Other income | PBT | Net profit |
|---|---|---|---|---|---|---|---|
| Sept 2026 | 519 | +13.8% | 123 | 23.7% | 99 | 146 | 130 |
| Jun 2026 | 489 | +12.9% | 104 | 21.3% | 32 | 59 | 48 |
| Mar 2026 | 461 | +18.8% | 110 | 23.9% | 4 | 37 | 25 |
| Dec 2025 | 443 | +20.7% | 99 | 22.3% | 21 | 34 | 28 |
| Sept 2025 | 456 | +27.7% | 100 | 21.9% | 114 | 135 | 125 |
| Jun 2025 | 433 | +30.0% | 88 | 20.3% | 57 | 63 | 52 |
| Mar 2025 | 388 | +26.4% | 71 | 18.3% | −27 | −39 | −42 |
| Dec 2024 | 367 | +26.1% | 67 | 18.3% | 40 | 51 | 40 |
Balance sheet
| As of | Equity | Debt | Investments | Fixed assets | CWIP | Total assets |
|---|---|---|---|---|---|---|
| Sept 2026 | 9,404 | 1,945 | 10,092 | 1,272 | 97 | 12,146 |
| Mar 2026 | 9,229 | 2,078 | 10,071 | 1,266 | 95 | 11,994 |
| Sept 2025 | 9,429 | 3,195 | 220 | 11,703 | 306 | 15,013 |
| Mar 2025 | 9,074 | 2,039 | 10,178 | 925 | 42 | 11,999 |
Cash flow
| Year end | Operating | Investing | Financing | Free cash flow |
|---|---|---|---|---|
| Mar 2026 | 116 | 11 | −176 | −190 |
| Mar 2025 | 334 | −1,572 | 1,276 | −31 |
| Mar 2024 | 218 | 44 | −245 | 44 |
| Mar 2023 | 198 | 205 | −395 | 145 |